IN-VIVO EVALUATION OF SPRAY FORMULATIONS OF HUMAN INSULIN FOR NASAL DELIVERY

被引:40
|
作者
DONDETI, P [1 ]
ZIA, HS [1 ]
NEEDHAM, TE [1 ]
机构
[1] UNIV RHODE ISL,COLL PHARM,DEPT PHARMACEUT,KINGSTON,RI 02881
关键词
INSULIN; HUMAN; NASAL ADMINISTRATION; SPRAY FORMULATION; BIOADHESIVE POLYMER; MICROCRYSTALLINE CELLULOSE; PLASTOID; AMMONIUM GLYCYRRHIZINATE; GLYCYRRHETINIC ACID; SODIUM TAUROCHOLATE;
D O I
10.1016/0378-5173(95)00045-K
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
There are many ongoing investigations to improve the nasal bioavailability of peptide and protein formulations. The presence of bioadhesive polymers in nasal formulations may increase the residence time of the drugs in the nasal cavity. A combination of bioadhesive polymers with permeation enhancers would seem to further improve nasal bioavailability. In this study, insulin spray formulations containing two bioadhesive polymers (1.5% w/v microcrystalline cellulose (MCC) and 70% w/w Plastoid L50) alone or in combination with the enhancers such as sodium taurocholate (ST), ammonium glycyrrhizinate (AG) or glycyrrhetinic acid (GA) at 1% w/v level, were evaluated in diabetic rabbits. A total volume of 100 mu l of freshly prepared insulin formulation was sprayed into the nasal cavity of each diabetic rabbit. Glucose levels were monitored using a blood glucose assay and serum insulin levels were analyzed using RIA. 5 U/kg insulin in the MCC suspension alone resulted in an absolute bioavailability of 1.96% while Plastoid L50 alone resulted in 2.25% absolute bioavailability. Insulin in the MCC suspension and ST, AG or GA resulted in 8.36, 7.83 and 2.15% bioavailability, respectively. The same formulations produced a hypoglycemic effect in terms of total glucose reductions of 39.12, 15.96 and 9.36% and the maximal decreases in glucose levels were 58.37, 21.8 and 18.61%, respectively. The Plastoid formulation containing 1% ST provided nasal insulin bioavailability of 5.9% with a total glucose reduction of 17.03% and a maximal glucose decrease of 26.56%. Insulin spray formulations containing 1% ST alone and 1% AG alone resulted in bioavailabilities of 7.25 and 3.57%, respectively. These same sprays provided total glucose reductions of 25.08 and 16.97% with maximal glucose decreases of 44.56 and 19.81%, respectively. The presence of benzalkonium chloride and 2-phenylethanol as preservatives in the MCC suspension resulted in higher insulin absorption than the same formulation without preservatives (6.31% vs 1.96%).
引用
收藏
页码:91 / 105
页数:15
相关论文
共 50 条
  • [31] Design and in vivo evaluation of an oral delivery system for insulin
    Marschütz, MK
    Caliceti, P
    Bernkop-Schnürch, A
    PHARMACEUTICAL RESEARCH, 2000, 17 (12) : 1468 - 1474
  • [32] Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin
    Combe, B
    Cohen, C
    Aubin, F
    CALCIFIED TISSUE INTERNATIONAL, 1997, 61 (01) : 10 - 15
  • [33] Design and In Vivo Evaluation of An Oral Delivery System for Insulin
    Michaela K. Marschütz
    Paolo Caliceti
    Andreas Bernkop-Schnürch
    Pharmaceutical Research, 2000, 17 : 1468 - 1474
  • [34] REGULATION OF HUMAN INSULIN-RECEPTOR RNA SPLICING IN-VIVO
    NORGREN, S
    ZIERATH, J
    WEDELL, A
    WALLBERGHENRIKSSON, H
    LUTHMAN, H
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (04) : 1465 - 1469
  • [35] Towards the nasal delivery of insulin
    Nazar, Hamde
    Tsibouklis, John
    THERAPEUTIC DELIVERY, 2012, 3 (11) : 1241 - 1243
  • [36] A Comparison of the Deposition Patterns of Different Nasal Spray Formulations Using a Nasal Cast
    Pu, Yu
    Goodey, Adrian P.
    Fang, Xiuhua
    Jacob, Kuriakose
    AEROSOL SCIENCE AND TECHNOLOGY, 2014, 48 (09) : 930 - 938
  • [37] Evaluation of systemic exposure between two nasal spray formulations of mometasone furoate in healthy subjects
    Phatak, Mukul
    Chachad, Siddharth
    Purandare, Shrinivas
    Malhotra, Geena
    Gandhi, Kalindi
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [38] RAT INSULIN TURNOVER IN-VIVO
    CANAS, X
    FERNANDEZLOPEZ, JA
    ARDEVOL, A
    ADAN, C
    ESTEVE, M
    RAFECAS, I
    REMESAR, X
    ALEMANY, M
    ENDOCRINOLOGY, 1995, 136 (09) : 3871 - 3876
  • [39] IN-VIVO BUCCAL DELIVERY OF CALCITONIN
    HEIBER, SJ
    EBERT, CD
    DAVE, SC
    SMITH, K
    KIM, SW
    MIX, D
    JOURNAL OF CONTROLLED RELEASE, 1994, 28 (1-3) : 269 - 271
  • [40] Aminated gelatin microspheres as a nasal delivery system for peptide drugs: Evaluation of in vitro release and in vivo insulin absorption in rats
    Wang, Jian
    Tabata, Yasuhiko
    Morimoto, Kazuhiro
    JOURNAL OF CONTROLLED RELEASE, 2006, 113 (01) : 31 - 37